Kodiak Sciences (NASDAQ:KOD) versus Genocea Biosciences (NASDAQ:GNCA) Head-To-Head Review

Kodiak Sciences (NASDAQ:KOD) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Earnings and Valuation

This table compares Kodiak Sciences and Genocea Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$260.49 million	($3.65)	-1.10
Genocea Biosciences	$1.91 million	0.00	-$33.20 million	($0.61)	N/A

Genocea Biosciences has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Kodiak Sciences and Genocea Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1	2	1	0	2.00
Genocea Biosciences	0	0	0	0	0.00

Kodiak Sciences currently has a consensus price target of $8.00, indicating a potential upside of 99.50%. Given Kodiak Sciences’ stronger consensus rating and higher possible upside, research analysts plainly believe Kodiak Sciences is more favorable than Genocea Biosciences.

Volatility and Risk

Kodiak Sciences has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Institutional and Insider Ownership

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 45.3% of Kodiak Sciences shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Kodiak Sciences and Genocea Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-84.52%	-45.40%
Genocea Biosciences	N/A	-182.88%	-62.76%

Summary

Kodiak Sciences beats Genocea Biosciences on 8 of the 12 factors compared between the two stocks.

About Kodiak Sciences

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.